代谢综合征对认知障碍影响的研究进展
Research Progress on the Impact of Metabolic Syndrome on Cognitive Impairment
DOI: 10.12677/acm.2025.1582193, PDF,   
作者: 肖 婷, 曹 婵：延安大学医学院，陕西 延安；刘 强*：延安大学附属医院神经内科，陕西 延安
关键词: 代谢综合征；认知障碍；影响机制；干预途径；Metabolic Syndrome； Cognitive Impairment； Impact Mechanisms； Intervention Approaches
摘要: 近年来，代谢综合征(MetS)与认知障碍的关联机制及干预策略日益受到重视。本文系统综述了MetS影响认知功能的研究进展，重点从以下病理生理机制展开阐述：(1) 中枢神经系统功能异常(涵盖海马体损伤、中枢胰岛素抵抗、氧化应激及瘦素抵抗)；(2) 外周信号介导机制(涉及高甘油三酯血症、慢性低度炎症、下丘脑–垂体–肾上腺轴失调)；(3) 血管性因素(以脑血流灌注不足为核心)。在干预领域，归纳了生活方式干预(饮食调控、运动疗法)、药物治疗(降糖/调脂/降压/神经保护剂)、心理干预等多模式临床路径。文末总结指出，当前研究仍需深化机制探索(尤其肠–脑轴与表观遗传调控)、优化循证干预方案，并加强跨学科协作，以制定精准化防治策略，应对MetS相关认知衰退的公共卫生挑战。
Abstract: In recent years, the pathogenic mechanisms linking metabolic syndrome (MetS) to cognitive impairment and corresponding intervention strategies have garnered increasing attention. This systematic review summarizes research advances on the impact of MetS on cognitive function, focusing on the following pathophysiological mechanisms: (1) Central nervous system dysfunction (encompassing hippocampal damage, central insulin resistance, oxidative stress, and leptin resistance); (2) Peripheral signaling-mediated mechanisms (involving hypertriglyceridemia, chronic low-grade inflammation, and hypothalamic-pituitary-adrenal axis dysregulation); and (3) Vascular factors (centered on cerebral hypoperfusion). In the intervention domain, the review outlines multimodal clinical pathways including lifestyle interventions (dietary regulation, exercise therapy), pharmacotherapy (hypoglycemic, lipid-lowering, antihypertensive, and neuroprotective agents), and psychological interventions. The article concludes by noting that current research still needs to deepen mechanistic exploration (especially the gut-brain axis and epigenetic regulation), optimize evidence-based intervention protocols, and strengthen interdisciplinary collaboration to formulate precise prevention and treatment strategies addressing the public health challenge of MetS-associated cognitive decline.
文章引用：肖婷, 刘强, 曹婵. 代谢综合征对认知障碍影响的研究进展[J]. 临床医学进展, 2025, 15(8): 19-27. https://doi.org/10.12677/acm.2025.1582193

参考文献

[1] Eckel, R.H., Alberti, K., Grundy, S.M. and Zimmet, P.Z. (2010) The Metabolic Syndrome. The Lancet, 375, 181-183. [Google Scholar] [CrossRef] [PubMed]
[2] Zouridis, S., Nasir, A.B., Aspichueta, P. and Syn, W. (2024) The Link between Metabolic Syndrome and the Brain. Digestion, 106, 203-211. [Google Scholar] [CrossRef] [PubMed]
[3] Przybycien-Gaweda, P.M., Gwee, X., Gao, Q., Chua, D.Q.L., Fam, J. and Ng, T.P. (2020) Metabolic Syndrome and Cognition: Follow-Up Study of Chinese Over-55-Year-Olds. Dementia and Geriatric Cognitive Disorders, 49, 129-137. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, J., Zhang, L., Liu, J., Yang, W. and Ma, L. (2021) Metabolic Syndrome, Apoe Genotype, and Cognitive Dysfunction in an Elderly Population: A Single-Center, Case-Control Study. World Journal of Clinical Cases, 9, 1005-1015. [Google Scholar] [CrossRef] [PubMed]
[5] Lai, M.M.Y., Ames, D.J., Cox, K.L., Ellis, K.A., Sharman, M.J., Hepworth, G., et al. (2020) Association between Cognitive Function and Clustered Cardiovascular Risk of Metabolic Syndrome in Older Adults at Risk of Cognitive Decline. The Journal of Nutrition, Health and Aging, 24, 300-304. [Google Scholar] [CrossRef] [PubMed]
[6] Buyo, M., Takahashi, S., Iwahara, A., Tsuji, T., Yamada, S., Hattori, S., et al. (2020) Metabolic Syndrome and Cognitive Function: Cross-Sectional Study on Community-Dwelling Non-Demented Older Adults in Japan. The Journal of Nutrition, Health and Aging, 24, 878-882. [Google Scholar] [CrossRef] [PubMed]
[7] Bahchevanov, K.M., Dzhambov, A.M., Chompalov, K.A., Massaldjieva, R.I., Atanassova, P.A. and Mitkov, M.D. (2020) Contribution of Components of Metabolic Syndrome to Cognitive Performance in Middle-Aged Adults. Archives of Clinical Neuropsychology, 36, 498-506. [Google Scholar] [CrossRef] [PubMed]
[8] González, H.M., Tarraf, W., Vásquez, P., Sanderlin, A.H., Rosenberg, N.I., Davis, S., et al. (2018) Metabolic Syndrome and Neurocognition among Diverse Middle-Aged and Older Hispanics/Latinos: HCHS/SOL Results. Diabetes Care, 41, 1501-1509. [Google Scholar] [CrossRef] [PubMed]
[9] Mehra, A., Suri, V., Kumari, S., Avasthi, A. and Grover, S. (2020) Association of Mild Cognitive Impairment and Metabolic Syndrome in Patients with Hypertension. Asian Journal of Psychiatry, 53, Article ID: 102185. [Google Scholar] [CrossRef] [PubMed]
[10] Ou, Y., Lee, J., Huang, S., Chen, S., Geng, J. and Su, C. (2023) Association between Menopause, Postmenopausal Hormone Therapy and Metabolic Syndrome. Journal of Clinical Medicine, 12, Article No. 4435. [Google Scholar] [CrossRef] [PubMed]
[11] Pathirana, M.M., Lassi, Z.S., Ali, A., Arstall, M.A., Roberts, C.T. and Andraweera, P.H. (2020) Association between Metabolic Syndrome and Gestational Diabetes Mellitus in Women and Their Children: A Systematic Review and Meta-analysis. Endocrine, 71, 310-320. [Google Scholar] [CrossRef] [PubMed]
[12] Kazlauskaite, R., Janssen, I., Wilson, R.S., Appelhans, B.M., Evans, D.A., Arvanitakis, Z., et al. (2020) Is Midlife Metabolic Syndrome Associated with Cognitive Function Change? The Study of Women’s Health across the Nation. The Journal of Clinical Endocrinology & Metabolism, 105, e1093-e1105. [Google Scholar] [CrossRef] [PubMed]
[13] Lu, R., Aziz, N.A., Diers, K., Stöcker, T., Reuter, M. and Breteler, M.M.B. (2021) Insulin Resistance Accounts for Metabolic Syndrome‐Related Alterations in Brain Structure. Human Brain Mapping, 42, 2434-2444. [Google Scholar] [CrossRef] [PubMed]
[14] De la Rosa, A., Olaso-Gonzalez, G., Arc-Chagnaud, C., Millan, F., Salvador-Pascual, A., García-Lucerga, C., et al. (2020) Physical Exercise in the Prevention and Treatment of Alzheimer’s Disease. Journal of Sport and Health Science, 9, 394-404. [Google Scholar] [CrossRef] [PubMed]
[15] Ali, N.H., Al‐Kuraishy, H.M., Al‐Gareeb, A.I., Alexiou, A., Papadakis, M., Bahaa, M.M., et al. (2024) New Insight on the Potential Detrimental Effect of Metabolic Syndrome on the Alzheimer Disease Neuropathology: Mechanistic Role. Journal of Cellular and Molecular Medicine, 28, e70118. [Google Scholar] [CrossRef] [PubMed]
[16] Spinelli, M., Fusco, S. and Grassi, C. (2020) Brain Insulin Resistance Impairs Hippocampal Plasticity. In: Vitamins and Hormones, Elsevier, 281-306. [Google Scholar] [CrossRef] [PubMed]
[17] Pan, W., Zhao, J., Wu, J., Xu, D., Meng, X., Jiang, P., et al. (2023) Dimethyl Itaconate Ameliorates Cognitive Impairment Induced by a High-Fat Diet via the Gut-Brain Axis in Mice. Microbiome, 11, Article No. 30. [Google Scholar] [CrossRef] [PubMed]
[18] Park, Y.H., Shin, S.J., Kim, H.S., Hong, S.B., Kim, S., Nam, Y., et al. (2020) Omega-3 Fatty Acid-Type Docosahexaenoic Acid Protects against Aβ-Mediated Mitochondrial Deficits and Pathomechanisms in Alzheimer’s Disease-Related Animal Model. International Journal of Molecular Sciences, 21, Article No. 3879. [Google Scholar] [CrossRef] [PubMed]
[19] Batiha, G.E., Al-Kuraishy, H.M., Al-Gareeb, A.I. and Elekhnawy, E. (2022) SIRT1 Pathway in Parkinson’s Disease: A Faraway Snapshot but So Close. Inflammopharmacology, 31, 37-56. [Google Scholar] [CrossRef] [PubMed]
[20] Martemucci, G., Fracchiolla, G., Muraglia, M., Tardugno, R., Dibenedetto, R.S. and D’Alessandro, A.G. (2023) Metabolic Syndrome: A Narrative Review from the Oxidative Stress to the Management of Related Diseases. Antioxidants, 12, Article No. 2091. [Google Scholar] [CrossRef] [PubMed]
[21] Więckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M. and Wojda, U. (2021) Western Diet as a Trigger of Alzheimer’s Disease: From Metabolic Syndrome and Systemic Inflammation to Neuroinflammation and Neurodegeneration. Ageing Research Reviews, 70, Article ID: 101397. [Google Scholar] [CrossRef] [PubMed]
[22] Watts, G.F. and Mamo, J.C.L. (2020) Hypertriglyceridemia and Alzheimer Disease: Opening the Mind to New Therapeutic Opportunities. Clinical Chemistry, 67, 6-8. [Google Scholar] [CrossRef] [PubMed]
[23] Nordestgaard, L.T., Christoffersen, M., Afzal, S., Nordestgaard, B.G., Tybjærg-Hansen, A. and Frikke-Schmidt, R. (2020) triglycerides as a Shared Risk Factor between Dementia and Atherosclerotic Cardiovascular Disease: A Study of 125 727 Individuals. Clinical Chemistry, 67, 245-255. [Google Scholar] [CrossRef] [PubMed]
[24] Lyra e Silva, N.M., Gonçalves, R.A., Pascoal, T.A., Lima-Filho, R.A.S., Resende, E.d.P.F., Vieira, E.L.M., et al. (2021) Pro-Inflammatory Interleukin-6 Signaling Links Cognitive Impairments and Peripheral Metabolic Alterations in Alzheimer’s Disease. Translational Psychiatry, 11, Article No. 251. [Google Scholar] [CrossRef] [PubMed]
[25] Lopez-Lopez, A., Valenzuela, R., Rodriguez-Perez, A.I., Guerra, M.J., Labandeira-Garcia, J.L. and Muñoz, A. (2023) Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia. Antioxidants, 12, Article No. 1454. [Google Scholar] [CrossRef] [PubMed]
[26] Khan, M.H., Pathan, S., Ansari, K., Baig, S., Ghafoor, A., Minhas, M., et al. (2025) Comparative Risk Assessment in Hypertensive Patients with Metabolic Syndrome by Exploring Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Cureus, 17, e85564. [Google Scholar] [CrossRef] [PubMed]
[27] Alzarea, E.A., Al-Kuraishy, H.M., Al-Gareeb, A.I., Alexiou, A., Papadakis, M., Beshay, O.N., et al. (2025) The Conceivable Role of Metabolic Syndrome in the Pathogenesis of Alzheimer’s Disease: Cellular and Subcellular Alterations in Underpinning a Tale of Two. NeuroMolecular Medicine, 27, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[28] Portero-Tresserra, M., Galofré-López, N., Pallares, E., Gimenez-Montes, C., Barcia, C., Granero, R., et al. (2023) Effects of Caloric Restriction on Spatial Object Recognition Memory, Hippocampal Neuron Loss and Neuroinflammation in Aged Rats. Nutrients, 15, Article No. 1572. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, J., Bai, Y., Zeng, Z., Wang, J., Wang, P., Zhao, Y., et al. (2022) Association between Life-Course Cigarette Smoking and Metabolic Syndrome: A Discovery-Replication Strategy. Diabetology & Metabolic Syndrome, 14, Article No. 11. [Google Scholar] [CrossRef] [PubMed]
[30] Åberg, F., Byrne, C.D., Pirola, C.J., Männistö, V. and Sookoian, S. (2023) Alcohol Consumption and Metabolic Syndrome: Clinical and Epidemiological Impact on Liver Disease. Journal of Hepatology, 78, 191-206. [Google Scholar] [CrossRef] [PubMed]
[31] Gonzalez-Cano, S.I., Flores, G., Guevara, J., Morales-Medina, J.C., Treviño, S. and Diaz, A. (2023) Polyoxidovanadates a New Therapeutic Alternative for Neurodegenerative and Aging Diseases. Neural Regeneration Research, 19, 571-577. [Google Scholar] [CrossRef] [PubMed]
[32] Du, M., Gao, Q., Liu, C., Bai, L., Li, T. and Wei, F. (2022) Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 14, Article ID: 838173. [Google Scholar] [CrossRef] [PubMed]
[33] Onaolapo, A.Y., Ojo, F.O., Adeleye, O.O., Falade, J. and Onaolapo, O.J. (2023) Diabetes Mellitus and Energy Dysmetabolism in Alzheimer’s Disease: Understanding the Relationships and Potential Therapeutic Targets. Current Diabetes Reviews, 19, e020123212333. [Google Scholar] [CrossRef] [PubMed]
[34] Hölscher, C. (2024) Glucagon-Like Peptide-1 Class Drugs Show Clear Protective Effects in Parkinson’s and Alzheimer’s Disease Clinical Trials: A Revolution in the Making? Neuropharmacology, 253, Article ID: 109952. [Google Scholar] [CrossRef] [PubMed]
[35] Siddeeque, N., Hussein, M.H., Abdelmaksoud, A., Bishop, J., Attia, A.S., Elshazli, R.M., et al. (2024) Neuroprotective Effects of GLP-1 Receptor Agonists in Neurodegenerative Disorders: A Large-Scale Propensity-Matched Cohort Study. International Immunopharmacology, 143, Article ID: 113537. [Google Scholar] [CrossRef] [PubMed]
[36] Fakih, W., Zeitoun, R., AlZaim, I., Eid, A.H., Kobeissy, F., Abd‐Elrahman, K.S., et al. (2022) Early Metabolic Impairment as a Contributor to Neurodegenerative Disease: Mechanisms and Potential Pharmacological Intervention. Obesity, 30, 982-993. [Google Scholar] [CrossRef] [PubMed]
[37] Varmazyar, R., Noori-Zadeh, A., Abbaszadeh, H.A., Hamidabadi, H.G., Rajaei, F., Darabi, S., et al. (2019) Neural Stem Cells Neuroprotection by Simvastatin via Autophagy Induction and Apoptosis Inhibition. Bratislava Medical Journal, 120, 744-751. [Google Scholar] [CrossRef] [PubMed]
[38] Huang, W., Li, Z., Zhao, L. and Zhao, W. (2017) Simvastatin Ameliorate Memory Deficits and Inflammation in Clinical and Mouse Model of Alzheimer’s Disease via Modulating the Expression of miR-106b. Biomedicine & Pharmacotherapy, 92, 46-57. [Google Scholar] [CrossRef] [PubMed]
[39] Torrandell‐Haro, G., Branigan, G.L., Vitali, F., Geifman, N., Zissimopoulos, J.M. and Brinton, R.D. (2020) Statin Therapy and Risk of Alzheimer’s and Age‐Related Neurodegenerative Diseases. Alzheimer’s & Dementia, 6, e12108. [Google Scholar] [CrossRef] [PubMed]
[40] Rodriguez‐Ortiz, C.J., Thorwald, M.A., Rodriguez, R., Mejias‐Ortega, M., Kieu, Z., Maitra, N., et al. (2022) Angiotensin Receptor Blockade with Olmesartan Alleviates Brain Pathology in Obese OLETF Rats. Clinical and Experimental Pharmacology and Physiology, 50, 228-237. [Google Scholar] [CrossRef] [PubMed]
[41] Crespo, M.C., Tomé‐Carneiro, J., Pintado, C., Dávalos, A., Visioli, F. and Burgos‐Ramos, E. (2017) Hydroxytyrosol Restores Proper Insulin Signaling in an Astrocytic Model of Alzheimer’s Disease. BioFactors, 43, 540-548. [Google Scholar] [CrossRef] [PubMed]
[42] Kokkeler, K.J.E., Marijnissen, R.M., Wardenaar, K.J., Rhebergen, D., van den Brink, R.H.S., van der Mast, R.C., et al. (2020) Subtyping Late-Life Depression According to Inflammatory and Metabolic Dysregulation: A Prospective Study. Psychological Medicine, 52, 515-525. [Google Scholar] [CrossRef] [PubMed]
[43] Alrefaie, Z., Ali, S.S. and Hamed, E.A. (2022) Elevated Hippocampal Mglut2 Receptors in Rats with Metabolic Syndrome-Induced-Memory Impairment, Possible Protection by Vitamin D. Brain Research Bulletin, 180, 108-117. [Google Scholar] [CrossRef] [PubMed]
[44] Hajjeh, O., Rajab, I., Bdair, M., Saife, S., Zahran, A., Nazzal, I., et al. (2025) Enteric Nervous System Dysfunction as a Driver of Central Nervous System Disorders: The Forgotten Brain in Neurological Disease. Neuroscience, 572, 232-247. [Google Scholar] [CrossRef] [PubMed]

为你推荐